Organon

Organon, a US-based Pharmaceutical Preparation Manufacturing company, reported approximately 1.09 billion kg CO2e in total gross global emissions for 2022. This includes about 30.36 million kg CO2e from Scope 1, approximately 30.91 million kg CO2e from Scope 2 (market-based), and around 1.03 billion kg CO2e from Scope 3 emissions. Their Scope 3 emissions in 2022 were primarily driven by purchased goods and services, accounting for approximately 765 million kg CO2e, and use of sold products, at about 61 million kg CO2e.

In 2021, Organon's reported Scope 1 emissions were approximately 32.01 million kg CO2e, and Scope 2 (market-based) emissions were about 31.84 million kg CO2e. For 2020, Scope 1 emissions were around 30.52 million kg CO2e, and Scope 2 (market-based) emissions were approximately 32.91 million kg CO2e. Scope 3 data was not disclosed for 2020 and 2021.

Organon aims to reduce its combined Scope 1 and Scope 2 GHG emissions by over 25% from 2020 levels by 2025. This near-term absolute reduction target applies to both Scope 1 and Scope 2 emissions.